Clinical Trial Update: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 trial of TransCon PTH in adults with hypoparathyroidism has completed, with results posted in 2023 evaluating safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• TransCon PTH (teriparatide)

Snippet

Sponsor: Ascendis Pharma A/S | Conditions: Hypoparathyroidism, Endocrine System Diseases | Phase 2 | Status: COMPLETED | Results posted: 2023-09-01